JP2023531802A - トリメタジジンの改変形態の調節放出製剤 - Google Patents

トリメタジジンの改変形態の調節放出製剤 Download PDF

Info

Publication number
JP2023531802A
JP2023531802A JP2022581463A JP2022581463A JP2023531802A JP 2023531802 A JP2023531802 A JP 2023531802A JP 2022581463 A JP2022581463 A JP 2022581463A JP 2022581463 A JP2022581463 A JP 2022581463A JP 2023531802 A JP2023531802 A JP 2023531802A
Authority
JP
Japan
Prior art keywords
imb
trimetazidine
hours
dose
hpmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531802A5 (https=
Inventor
アンドリュー ディー． レビン，
ジャイクリシュナ パテル，
ジョージ ムーニー，
スコット ハービッグ，
Original Assignee
インブリア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インブリア ファーマシューティカルズ， インコーポレイテッド filed Critical インブリア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023531802A publication Critical patent/JP2023531802A/ja
Publication of JP2023531802A5 publication Critical patent/JP2023531802A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022581463A 2020-06-30 2021-06-28 トリメタジジンの改変形態の調節放出製剤 Pending JP2023531802A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063046117P 2020-06-30 2020-06-30
US202063046115P 2020-06-30 2020-06-30
US63/046,117 2020-06-30
US63/046,115 2020-06-30
US202163183299P 2021-05-03 2021-05-03
US202163183294P 2021-05-03 2021-05-03
US63/183,299 2021-05-03
US63/183,294 2021-05-03
PCT/US2021/039303 WO2022005926A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Publications (2)

Publication Number Publication Date
JP2023531802A true JP2023531802A (ja) 2023-07-25
JP2023531802A5 JP2023531802A5 (https=) 2024-06-21

Family

ID=79315460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581463A Pending JP2023531802A (ja) 2020-06-30 2021-06-28 トリメタジジンの改変形態の調節放出製剤

Country Status (8)

Country Link
EP (1) EP4171232A4 (https=)
JP (1) JP2023531802A (https=)
KR (1) KR20230028535A (https=)
CN (1) CN116234555A (https=)
AU (1) AU2021299197A1 (https=)
CA (1) CA3187827A1 (https=)
IL (1) IL299544A (https=)
WO (1) WO2022005926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539802A (ja) * 2006-06-09 2009-11-19 シュバルツ ファルマ アクチェンゲゼルシャフト フェソテロジンを含む安定した医薬組成物
JP2016527261A (ja) * 2013-08-01 2016-09-08 ヴァルファルマ インターナショナル ソチエタ ペル アツィオーニ グリクラジドを含有する放出調節医薬品製剤
WO2018236745A1 (en) * 2017-06-20 2018-12-27 Carnot, Llc COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CARDIAC METABOLISM
JP2019507771A (ja) * 2016-03-09 2019-03-22 エヌエルエス−１ ファルマ アーゲー マジンドールのｉｒ／ｓｒ多層錠剤及び該錠剤の注意欠陥／多動性障害（ａｄｈｄ）の治療のための使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539802A (ja) * 2006-06-09 2009-11-19 シュバルツ ファルマ アクチェンゲゼルシャフト フェソテロジンを含む安定した医薬組成物
JP2016527261A (ja) * 2013-08-01 2016-09-08 ヴァルファルマ インターナショナル ソチエタ ペル アツィオーニ グリクラジドを含有する放出調節医薬品製剤
JP2019507771A (ja) * 2016-03-09 2019-03-22 エヌエルエス−１ ファルマ アーゲー マジンドールのｉｒ／ｓｒ多層錠剤及び該錠剤の注意欠陥／多動性障害（ａｄｈｄ）の治療のための使用
WO2018236745A1 (en) * 2017-06-20 2018-12-27 Carnot, Llc COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CARDIAC METABOLISM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT. J. PHARM. PHARMACEUT. RES., vol. Vol.13 Iss.1, JPN6025024686, 2018, pages 43 - 71, ISSN: 0005621936 *

Also Published As

Publication number Publication date
EP4171232A1 (en) 2023-05-03
IL299544A (en) 2023-02-01
CA3187827A1 (en) 2022-01-06
WO2022005926A1 (en) 2022-01-06
KR20230028535A (ko) 2023-02-28
CN116234555A (zh) 2023-06-06
AU2021299197A1 (en) 2023-02-02
EP4171232A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20120208854A1 (en) Therapeutic combination
US20230255942A1 (en) Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
UA75027C2 (uk) Спосіб лікування серцево-судинних захворювань лікарською формою ранолазину пролонгованої дії
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
EP3720433B1 (en) Bis-choline tetrathiomolybdate for treating wilson disease
US12048768B2 (en) Gastro-resistant controlled release oral dosage forms
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
US12011506B2 (en) Combination and uses and treatments thereof
JP2023531802A (ja) トリメタジジンの改変形態の調節放出製剤
JP2025514817A (ja) 胃不全麻痺を処置するための重水素化ドンペリドン
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
Sakr et al. Pharmacokinetics of buspirone extended‐release tablets: a single‐dose study
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
JP2024540172A (ja) 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法
US20070053975A1 (en) Ramipril formulation
US20240041817A1 (en) Methods of providing solriamfetol therapy to subjects with impaired renal function
US20240091159A1 (en) Combination and Uses and Treatments Thereof
JPH11322584A (ja) ベザフィブラート徐放性製剤
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
Tablets et al. PrJAMP Pioglitazone
Tablets et al. PrTEVA-DILTIAZEM XC
EA047001B1 (ru) Лекарственные формы малеата акалабрутиниба
Tablets et al. Pr SANDOZ SAXAGLIPTIN
Hydrochloride et al. PrMYLAN-PIOGLITAZONE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260402